Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

NCT03304639 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03304639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03304639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2018
Completion date
February 19, 2026
Enrollment
9 (actual)
Sites
254

Conditions

As the registry lists them; a condition with its own page is linked.

advanced merkel cell carcinoma, clinical stage iii cutaneous merkel cell carcinoma ajcc v8, clinical stage iv cutaneous merkel cell carcinoma ajcc v8, metastatic merkel cell carcinoma, pathologic stage iii cutaneous merkel cell carcinoma ajcc v8, pathologic stage iiia cutaneous merkel cell carcinoma ajcc v8, pathologic stage iiib cutaneous merkel cell carcinoma ajcc v8, pathologic stage iv cutaneous merkel cell carcinoma ajcc v8